Robert Seeger, MD, Division Head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles (CHLA), has been selected for the 2016 Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMTC).
Robert Seeger, MD
As the eighth recipient of the prestigious award, Dr. Seeger is recognized for a career that exemplifies the mission of the PBMTC to support research and education to improve the availability, safety, and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents.
Dr. Seeger, who has served as Director of the Cancer Research Program in The Saban Research Institute of CHLA since 1995, has been at the forefront of cancer immunotherapy and genetics for decades.
Few have had as much of an impact on the understanding and treatment of a single disease as Dr. Seeger has had on neuroblastoma—from his contributions to the creation of dinutuximab (Unituxin), to his work on genetically based risk stratification for neuroblastoma patients, to identifying and treating patients with residual neuroblastoma posttreatment.
In 2000, as part of his effort to expand therapeutic possibilities for neuroblastoma patients, he cofounded the New Approaches to Neuroblastoma Therapy Consortium, which is based at CHLA.
In addition to being a world-class researcher, physician, author, and advisor, Dr. Seeger is also Professor of Pediatrics in the Keck School of Medicine of the University of Southern California and has mentored scientists and physicians who have become leaders in the field. ■
